XNK Therapeutics AB’s CEO Johan Liwing will present at Redeye’s Regenerative Medicine/Cell Therapy event on February 22 between 09:00-12:00 CET.
XNK’s presentation starts at 09:10 and is followed at 09:55 by a panel discussion regarding cell therapy for cancer.
The presentation is broadcasted live starting at 09:00 and can be followed at: https://www.redeye.se/events/868745/redeye-theme-regenerative-medicine-cell-therapy-2
For more information, please contact:
Johan Liwing, CEO, XNK Therapeutics
Tel: +46 706 70 36 75
E-mail: johan.liwing@xnktherapeutics.com
About XNK Therapeutics AB
XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on treating cancer by developing novel NK cell-based therapies. The company is at the forefront of the development of autologous NK cell-based products using its proprietary technology platform. The company’s platform technology and lead investigational candidate drug is developed specifically to target cancers, including settings where allogeneic cell products are not readily applicable. The Company’s objective is for its NK cell-based products to constitute key components in the cancer treatments of tomorrow. XNK Therapeutics is headquartered in Stockholm, Sweden. For more info, please visit http://www.xnktherapeutics.com
